Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice

被引:65
作者
Wu, WR [1 ]
Zhu, XZ [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol, Shanghai 200031, Peoples R China
关键词
Ginkgo biloba extract; ginkgolide A; ginkgolide B; MPTP; dopamine; striatum; HPLC; kynuramine; 4-hydroxyquinoline; monoamine oxidase; fluorescence;
D O I
10.1016/S0024-3205(99)00232-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The present study investigated the neuroprotective and neurorestorative effects of Ginkgo biloba extract (EGb 761) and its two components ginkgolides A (BN52020) and B (BN52021) in mice, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30 mg/kg/d ip for six days) significantly reduced striatal dopamine (DA) levels in C57 mice measured by high performance liquid chromatography with electrochemical detection (HPLC-EC). When C57 mice were pretreated with EGb 761 (20, 50, 100 mg/kg/d ip) for 7 days and then treated with the same extract 30 min before MPTP injection for 6 days, the neurotoxic effect of MPTP was antagonized in a dose-dependent fashion. Similar treatment with ginkgolides A and B (5, 10, 50 mg/kg/d ip) showed no protective effect. When C57 mice were treated with EGb 761 (50 mg/kg/d ip) after MPTP-lesion, the recovery of striatal dopamine (DA) levels was accelerated. However, similar treatment with ginkgolides A or B (10 mg/kg/d ip) did not show any effect. EGb 761, but not ginkgolides A and B, nonselectively inhibited mouse brain MAO activity in vitro (IC(50) = 36.45 +/- 1.56 mu g/ml) tested by an improved fluorimetric assay. The results demonstrate that EGb 761 administered before or after MPTP treatment effectively protects against MPTP-induced nigrostriatal dopaminergic neurotoxicity and that the inhibitory effect of EGb 761 on brain MAO may be involved in its neuroprotective effect.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 29 条
[1]  
BARQUET PG, 1991, MED RES REV, V11, P295
[2]  
BASCHEK V, 1988, INT CONGR SER, V791, P575
[3]  
BAUER U, 1984, ARZNEIMITTEL-FORSCH, V34-1, P716
[4]  
BRAQUET P, 1987, Drugs of the Future, V12, P643
[5]  
CHATTERJEE SS, 1982, ARCH PHARM S, V319, P57
[6]  
CHIUEH CC, 1986, MPTP NEUROTOXIN PROD, P473
[7]   BUFLOMEDIL - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN PERIPHERAL AND CEREBRAL VASCULAR DISEASES [J].
CLISSOLD, SP ;
LYNCH, S ;
SORKIN, EM .
DRUGS, 1987, 33 (05) :430-460
[8]  
DEFEUDIS FV, 1991, PHARM ACTIVITIES CLI, P97
[9]  
Halama P, 1988, Fortschr Med, V106, P408
[10]  
Hung H C, 1996, Brain Res Mol Brain Res, V41, P14